Tanguler Tolga 4

What Happened Tolga Tanguler, Executive Vice President and Chief Commercial Officer of Alnylam Pharmaceuticals, sold a total of 2,309 shares in multiple open-market transactions on March 4, 2026. The individual lots were: 106 @ $319.03 ($33,817); 102 @ $320.01 ($32,641); 215 @ $320.81 ($68,974); 289 @ $321.82 ($93,006); 350 @ $323.01 ($113,054); 767 @ $323.84 ($248,385); 272 @ $324.88 ($88,367); and 208 @ $325.67 ($67,739). Aggregate proceeds were about $745,983. These sales were reported on a Form 4 filed March 6, 2026.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
• Sale type: Open-market sales coded "S"; total 2,309 shares for ~$746K.
• Price range: reported prices/weighted averages span roughly $318.27 to $326.21 (footnotes indicate some prices are weighted averages across multiple executions).
• Footnotes: F1 indicates these were automatic sell-to-cover transactions by the company to satisfy minimum statutory tax withholding on vesting restricted stock units (RSUs). F2–F9 explain weighted-average pricing ranges and availability of breakdowns upon request.
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context

• These transactions are routine sell-to-cover tax-withholding sales tied to RSU vesting, not discretionary open-market liquidation for investment decisions. Such sales are common when RSUs vest and are generally considered administrative rather than a signal of insider sentiment.